Human papillomavirus type 16 and 18 viral clearance and progression to precancer among women aged 18–25 years enrolled in the Costa Rica HPV prophylactic vaccine trial (CVT)
Among young adult women without evidence of HSIL by cytology, clearance of prevalently detected HPV16/18 infection is a common event, and progression to precancer occurs infrequently but in a sizeable proportion of those with prevalent infection.
Authors
- Peter Dull
- Loretto J Carvajal (ORCID: https://orcid.org/0000-0002-4965-7615)
- Danping Liu (ORCID: https://orcid.org/0000-0001-5483-6303)
- Aimée R. Kreimer (ORCID: https://orcid.org/0000-0002-6073-2591)
- Ana Cecilia Rodríguez (ORCID: https://orcid.org/0000-0001-9866-2106)
- Mónica S. Sierra
- John Schussler (ORCID: https://orcid.org/0000-0002-8793-0766)
- Rebeca Ocampo (ORCID: https://orcid.org/0000-0002-8069-5142)
- John T. Schiller (ORCID: https://orcid.org/0000-0001-7308-950X)
- Rolando Herrero
- Douglas R. Lowy (ORCID: https://orcid.org/0000-0003-0635-219X)
- Carolina Porras (ORCID: https://orcid.org/0000-0002-4592-3883)
- Allan Hildesheim
Institutions
- Gates Foundation (US)
- Instituto Costarricense de Investigación y Enseñanza en Nutrición y Salud (CR)
- Information Management Services (US)
- National Cancer Institute (US)
- Division of Cancer Epidemiology and Genetics
Publication Details
- Journal
- Vaccine
- Published
- 2025-02-16
- DOI
- https://doi.org/10.1016/j.vaccine.2025.126841
- Citations
- 1
- Primary Topic
- Cervical Cancer and HPV Research
- Type
- article
- Field-Weighted Citation Impact
- 1.35
Funders
- National Cancer Center